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EDITORIAL
Antiangiogenic  therapy  in  metastatic  renal
cell  carcinoma:  More  promises  and  more
challenges  for  imaging
We  are  pleased  to  be  offered  the  opportunity  to  comment  on  the  article  by  Sami  Ammari
et  al.  [1].  The  authors  provide  a  comprehensive  and  excellent  description  of  the  current
imaging  challenges  of  metastatic  renal  cell  cancer  (RCC)  evaluation  after  antiangiogenic
therapy.The  use  of  antiangiogenic  therapy  for  the  treatment  of  RCC  has  revolutionized  the
treatment  of  this  disease.  Prior  standard  options  such  as  interferon  were  not  much  better
than  placebo  and  were  associated  with  substantial  toxicity  that  worsened  the  quality  of
life  of  many  patients.  Whether  interferon    and  interleukine-2  have  long  been  the  single
treatment  options  in  metastastic  RCC,  antiangiogenic  agents  such  as  sorafenib,  sunitinib,
bevacizumab  (in  combination  with  interferon)  [2],  pazopanib  and  mTOR  inhibitors  such  as
temsirolimus  [3]  and  everolimus  [4]  have  been  approved  in  the  past  few  years.
With  an  increasing  number  of  therapeutic  agents,  the  need  for  imaging  biomarkers
has  become  more  critical  than  ever  for  demonstrating  efﬁcacy  and  potentially  improving
the  cost—beneﬁt  ratio  of  the  treatment.  Assessment  of  the  response  of  metastatic  RCC
to  therapy  has  traditionally  been  based  on  changes  in  target  lesion  size.  However,  the
mechanism  of  action  of  antiangiogenic  therapies  often  leads  to  stabilization  rather  than
regression  with  regards  to  tumor  size.  This  particularity  in  tumor  response  makes  RECIST
1.1  [5]—a  system  whose  criteria  are  based  exclusively  on  tumor  size—inadequate  to  early
and  timely  determine  the  patients  who  may  take  advantage  of  the  treatment.  As  discussed
by  Ammari  et  al.  [1], after  antiangiogenic  therapy,  the  presence  of  necrosis,  which  appears
as  areas  of  hypoattenuation  on  computed  tomography  (CT),  is  associated  with  a  more  favor-
able  therapeutic  outcome  [6]. Previously,  hypoattenuating  lesions  that  developed  central
areas  of  enhancement  during  the  course  of  the  treatment  were  indicative  of  progressive
disease  [7].  Antiangiogenic  therapies  may  induce  early  extensive  necrosis  without  tumor
shrinkage  on  CT  images  during  and  after  treatment,  ﬁndings  that  may  sometimes  simulate
progressive  disease.  Given  the  morphologic  changes  induced  by  antiangiogenic  therapy,
new  classiﬁcations  that  rely  not  only  on  size  changes  but  also  on  attenuation  changes
have  been  developed  in  an  attempt  to  improve  the  early  assessment  of  both  the  treat-
ment  response  and  recurrences.  These  more  recent  classiﬁcations  for  evaluating  response
to  therapy  include  the  Choi  criteria,  modiﬁed  Choi  criteria,  and  Size  and  Attenuation  CT
(SACT)  criteria.  In  this  review,  the  authors  provide  a practical  approach  of  these  systems
by  explaining  their  differences,  their  limitations,  their  feasibility  and  reproducibility  [1].
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Besides  the  development  of  new  criteria  for  conven-
ional  imaging  methods,  biomarkers  and  new  functional
nd  molecular  imaging  technologies  that  provide  a quan-
itative  assessment  of  the  change  in  vascularity  have
een  introduced  [8].  These  techniques  include  dynamic
ontrast-enhanced  (DCE)  magnetic  resonance  imaging  (MRI),
ynamic  contrast-enhanced  CT,  dynamic  contrast-enhanced
ltrasound,  diffusion-weighted  MRI,  blood  oxygenation
evel-dependent  MRI  and  positron  emission  tomography
PET)  with  oxygen-labeled  water.  Each  of  these  techniques
rovides  quantitative  or  semi-quantitative  data  related  to
lood  ﬂow  and  some  can  also  provide  information  on  blood
olume,  cellularity  or  vessel  permeability.  To  date,  DCE-MRI
nd  FDG—PET-CT  are  the  most  developed  and  used  technolo-
ies.  They  hold  great  promise  for  the  future,  especially  due
o  their  potential  for  early  prediction  of  treatment  response
o  biotherapies,  thereby  preventing  unnecessary  treatment
ith  accompanying  adverse  events  and  high  costs.  More
ecently,  attempts  have  been  made  to  target  angiogenesis
n  imaging  (e.g.  selective  PET  tracers  targeting  integrins,
EGFR  [9],  EGFR  [10],  and  targeted  contrast-enhanced
ltrasound  imaging  [11])  and  will  be  possibly  other  potential
andidates  as  early  biomarkers.
Beyond  the  spectrum  of  antiangiogenic  therapy,  this
rticle  highlights  the  new  paradigm  in  cancer  care  where
edical  therapy  for  malignancy  is  jumping  from  standard
hemotherapy  to  personalized  medicine  with  targeted
molecular)  therapies  [12].  As  a  result,  the  future  of  imaging
ppears  to  have  already  skewed  toward  molecular  imag-
ng  and  hybrid  imaging.  But  besides  the  great  opportunities
ffered  by  new  imaging  technologies,  the  essential  but  ulti-
ate  challenge  will  be  to  demonstrate  the  clinical  beneﬁt
i.e.  in  overall  survival  and/or  in  quality  of  life)  of  any  can-
er  imaging  biomarker.  Radiologists  need  to  be  prepared,  as
t  will  mean  changes  in  training,  in  research  and  in  clinical
ractice.
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